Article
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Science (New York, N.Y.) - 16 Feb 2018
Miao Diana, Margolis Claire A, Gao Wenhua, Voss Martin H, Li Wei, Martini Dylan J, Norton Craig, Bossé Dominick, Wankowicz Stephanie M, Cullen Dana, Horak Christine, Wind-Rotolo Megan, Tracy Adam, Giannakis Marios, Hodi Frank Stephen, Drake Charles G, Ball Mark W, Allaf Mohamad E, Snyder Alexandra, Hellmann Matthew D, Ho Thai, Motzer Robert J, Signoretti Sabina, Kaelin William G, Choueiri Toni K, Van Allen Eliezer M
Abstract excerpt
Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1) improve survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To identify genomic alterations in ccRCC that correlate with response to anti-PD-1 monotherapy, we performed whole-exome sequencing of metastatic ccRCC from 35 patients. We found that clinical benefit was associated with loss-of-function...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.